江中藥業(600750.SH)間接控股子公司擬5.66億元建設中醫藥科創城現代化生產基地一期工程項目
格隆匯4月24日丨江中藥業(600750.SH)公佈,為夯實公司在中醫藥領域的業務基礎,助推企業內生增長與外延併購戰略實施,實現江西南昌桑海製藥有限責任公司(以下簡稱“桑海製藥”)、江西南昌濟生製藥有限責任公司(以下簡稱“濟生製藥”)在技術、裝備方面轉型升級,公司間接控股子公司將投資5.66億元建設中醫藥科創城現代化生產基地一期工程項目。
公司控股子公司桑海製藥、濟生製藥共同成立江西江中濟海製藥有限責任公司(以下簡稱“江中濟海”),以江中濟海為項目投資主體。
項目擬購地約400餘畝,建設內容包桑海製藥和濟生製藥搬遷、院內製劑及配套提取、宿舍、食堂、辦公等。規劃設計秉持高起點為原則,致力於打造一個“綠色、智能、經濟”的現代化“園區”式工廠,預計總建築面積8.5萬平方米,設計6個生產車間,各劑型設計年產能約為片劑10億片、膠囊13億粒、顆粒4億袋、口服液4.6億支。項目計劃2020年6月底前啟動實施,2023年6月底前項目建成竣工。
預計投資項目一期工程投資5.66億元,項目財務內部收益率約為10.73%;投資回收期(靜態)約為9.81年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.